Clinical Trials

• A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb®662 in Monotherapy or in Combination with Pembrolizumab in Advanced Solid Tumors
• Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors
• A Phase 1/1a Study of Venetoclax, MLN9708 (ixazomib citrate) and Dexamethasone for Relapsed/ Refractory Light Chain Amyloidosis
• A Phase IIIb, Single-Arm, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in Adult Patients with Polycythemia Vera (PV)
• A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma (AOST2031)
• A Phase 2 Trial of Chemotherapy followed by Response Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor (ACNS2021)
• A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors (AGCT1531)
• A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG). (ACNS1821)
• A Phase 3 Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children with Average-Risk Medulloblastoma and Reduced Therapy in Children with Medulloblastoma with Low-Risk Features (ACNS2031)
• APhase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND #145355) (ACNS1723)
• A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
• A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
• Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
• Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
• Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours (P3BEP)
• Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

• Acute Leukemia
• Study Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients
• Study For Patients With Newly Diagnosed Acute Myeloid Leukemia To See If Drugs for Treating Heart Problems May Help To Prevent Heart Problems
• A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations (AAML1831)
• Study for Patients with CD 123+ Acute Myeloid Leukemia (AML), Myelofibrosis (MF) or Chronic Myelomonocytic Leukemia (CML)

• Acute Lymphblastic Leukemia
• A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
• A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy (ACCL1931)

• Acute Myeloid Leukemia
• A Phase 1b Study of Menin Inhibitor SNDX-5613 in Combination with Daunorubicin and Cytarabine in Newly Diagnosed Patients with Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype with Higher-Risk Features or MLL/KMT2A Rearranged Disease

• Adult Chronic Kidney Disease
• A randomized, double-blind, multicenter, Phase 3 study to evaluate efficacy and safety of belumosudil in combination with corticosteroids versus placebo in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD)

• Advanced Solid Tumors
• A Phase 1 Study of KSQ-4279 Alone and In Combination In Patients with Advanced Cancer
• Phase 1 Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-6306 Alone or in Combination with RP-3500 in Patients with Advanced Solid Tumors
• A Phase 1/2 Research Study for Patients with Ovarian Clear Cell Carcinoma or Endometrial Carcinoma or other Advanced Solid Tumors

• Bile Duct Cancer
• A Phase 1b/2a Study of GNS561 in Combination with Trametinib in Advanced KRAS Mutated Cholangiocarcinoma
• A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308)

• Bladder Cancer
• Testing Anti-Cancer Drugs Erdafitinib with or without Atezolizumab in Patients with Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy
• Patients with a locally advanced or metastatic solid tumor cancers are needed for a study to research an investigational immunotherapy
• Research study for adults at risk, diagnosed with, or being evaluated for cancer
• A study of experimental combination of 2 drugs versus standard chemotherapy in patients with metastatic urothelial cancer
• Testing the role of DNA released from tumor cells into the blood in guiding the use of immunotherapy after surgical removal of the bladder for bladder cancer treatment.

• Brain Cancer
• Seeking Adults with Progressive Meningiomas
• GBM Agile, study for newly diagnoses and recurrent glioblastomas
• Adults with Recurrent Glioblastoma (GBM) are Invited to Participate in a Research Study
• Study for Adults with Primary Central Nervous System Lymphoma (PCNSL)

• Brain Tumor
• Seeking Adults with Progressive Meningiomas
• GBM Agile, study for newly diagnoses and recurrent glioblastomas
• Study for Adults with Primary Central Nervous System Lymphoma (PCNSL)
• A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors (ACCL2031)

• BRCA1
• Research study for ovarian cancer patients with BRCA1 mutations to compare two surgical procedures

• Breast Cancer
• Patients with a locally advanced or metastatic solid tumor cancers are needed for a study to research an investigational immunotherapy
• A Phase II Study of Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)
• Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
• Patients with metastatic breast cancer are needed for a study to research an investigational drug combination involving an immunotherapy and a cellular therapy.
• The University of Virginia Cancer Center is seeking women age 65+ with early stage breast cancer for a trial investigating the Pre-Operative Window of adjuvant Endocrine therapy to inform Radiation therapy decisions (POWER)
• Adults with HER2 (Human Epidermal Growth Factor Receptor 2)-positive early breast cancer with residual invasive disease following preoperative chemotherapy and surgery invited to be in a research study
• Phase 1/2a Dose Escalation, Finding and Expansion Study Evaluating Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti Tumor Activity of PF-07104091 as a Single Agent and in Combination Therapy
• A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
• A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
• A Phase IIa Study of Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab in Patients with Asymptomatic Brain Metastasis from Triple Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC).
• A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
• Ph 3 Open-Label Randomized Study to Assess Efficacy/Safety of Camizestrant vs Standard Endocrine Therapy as Adj. Treatment for Patients with ER+/HER2- Early Breast Cancer at+Intermediate-High/High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
• A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)
• The POWER II Trial: Seeking women ages 65 years or older with early-stage, estrogen receptor positive (ER+) breast cancer.

• Carinoma
• Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere™) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy

• CarT
• A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible - EMN28 – EMagine / 68284528MMY3005- CARTITUDE-6

• Cell therapy
• A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible - EMN28 – EMagine / 68284528MMY3005- CARTITUDE-6

• Cervical Cancer
• Patients with a locally advanced or metastatic solid tumor cancers are needed for a study to research an investigational immunotherapy
• A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy with or without immunotherapy for the Treatment of Stages IB2-IIB, III and IVA Cervical Cancer
• Research study for adults with gynecological cancer
• A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)
• A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic, or Persistent Cervical Carcinoma
• A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)
• A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)

• Colorectal Cancer
• A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second-line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS or NRAS Mutation
• A phase I/II, first in human, open label, dose escalation study of a cancer-specific plectin (CSP)- targeting functional antibody in solid tumors that are likely to express CSP
• Study for Patients Planning to Undergo Abdominal Surgery for Colorectal, Hepatobiliary, or Gynecologic Cancer
• A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination with Immune Checkpoint Blockade for Patients with Metastatic Colorectal Cancer
• A phase 1b/2, master protocol evaluating the safety, tolerability, pharmacokinetics, and efficacy of sotorasib (AMG 510) in subjects with advanced solid tumors with KRAS p.G12C Mutation (CodeBreaK 101)
• A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS or NRAS Mutation
• Testing the addition of anti-cancer drug, ZEN003694, to the usual chemotherapy treatment, cetuximab plus encorafenib, for colorectal cancer
• Testing the use of BRAF-targeted therapy after surgery and usual chemotherapy for BRAF-mutated colon cancer

• Endometrial Cancer
• A Trial of Radiation Therapy for Adult Women with Early Stage Endometrial Cancer
• Adults with Endometrial cancers invited to be in a research study

• Endometriosis
• Research Study for Women who have Complex Atypical Hyperplasia OR Stage 1a Grade 1 Endometrial Cancer

• Esophageal Cancer
• Adults with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma invited to be in a research study
• A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

• Essential Thrombocythemia
• A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in Adult Patients with Essential Thrombocythemia

• Fallopian Tube Cancer
• Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer who are Folate Receptor a positive

• Focused Ultrasound Surgery
• Adults with Recurrent Glioblastoma (GBM) are Invited to Participate in a Research Study
• Study Seeking Adult Patients with Advanced Melanoma Who are Receiving Immune Therapy and Who are Planning to Receive Surgery

• Gastric Bypass
• A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-1200 in Participants with Advanced Solid Tumors

• Glioblastoma
• GBM Agile, study for newly diagnoses and recurrent glioblastomas
• Adults with Recurrent Glioblastoma (GBM) are Invited to Participate in a Research Study

• Gynecologic Cancer
• Study for Patients Planning to Undergo Abdominal Surgery for Colorectal, Hepatobiliary, or Gynecologic Cancer

• Head and Neck Cancer
• Patients with advanced head and neck cancer are needed for a study to research the combination of an experimental drug and radiation therapy
• Patients with recurrent and/or metastatic head and neck cancer with high-risk HPV16 infection are needed for a study to research an investigative therapy in combination with immunotherapy
• A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti–LAG-3) and INCAGN02390 (Anti–TIM-3) as First-Line Treatment in Participants With PD-L1–Positive (CPS = 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
• A Phase I/II Study of TheraT® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers
• A Phase 2 Study of Darolutamide in Combination with Leuprolide Acetate in Hormone-Therapy Naïve Recurrent and/ or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer
• RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer (KEVLARx)
• A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
• A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator’s choice monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinoma

• Healthy Subject Study
• Healthy Adults and Lung/Liver Cancer Patients are invited to be in a research study.

• Hormone Studies
• Research Study for Women who have Complex Atypical Hyperplasia OR Stage 1a Grade 1 Endometrial Cancer

• Incidental Pancreatic Mucinous Neoplasm (IPMN)
• EA2185 Study: Pancreatic Cyst Screening Comparing Two Methods to Follow Patients with Pancreatic Cysts

• Kidney Cancer
• A phase II multicenter study of lenvatinib plus everolimus versus cabozantinib in patients with metastatic renal cell carcinoma that progressed on a PD-1/PD-L1 checkpoint inhibitor
• A Phase 2 trial to evaluate the safety and efficacy of NKT2152 in Combination with Palbociclib (Doublet) and with Palbociclib and Sasanlimab (Triplet) in subjects with advanced or Metastatic Clear Cell Renal Cell Carcinoma.
• Comparing the outcome of immunotherapy-based drug combination therapy with or without surgery to remove the kidney in metastatic kidney cancer

• Kidney Disease
• Comparing the outcome of immunotherapy-based drug combination therapy with or without surgery to remove the kidney in metastatic kidney cancer

• Leukemia
• Study Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients
• A Phase 1, Open-Label, Study of Voruciclib in Subjects with Relapsed and/or Refractory B-Cell Malignancies or Acute Myeloid Leukemia After Failure of Prior Standard Therapies and Voruciclib in Combination with Venetoclax in Subjects with Relapsed and/or Refractory Acute Myeloid Leukemia
• A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients with Newly Diagnosed and Relapsed/Refractory Cancer Indications
• Study for Patients with High Risk Leukemias or Myelodysplastic Syndrome to Start Supportive Care Earlier in the Treatment Regimen
• Study For Patients With Newly Diagnosed Acute Myeloid Leukemia To See If Drugs for Treating Heart Problems May Help To Prevent Heart Problems
• A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects with Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
• A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations (AAML1831)
• Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia
• A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
• Randomized Phase 2 Study of daunorubicin and cytarabine liposome + Pomalidomide versus daunorubicin and cytarabine liposome in Newly Diagnosed AML with MDS-Related Changes
• Phase I/II Study of DFP-10917 in Combination with Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
• Phase 1/2 Multicenter, Open-Label Study of CTX-712 in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
• A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation
• A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
• A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of CC-486 (ORAL-AZA, ONUREG) in Subjects with Moderate or Severe Hepatic Impairment Compared with Normal Hepatic Function in Adult Subjects with Myeloid Malignancies
• A Phase 1b Study of Menin Inhibitor SNDX-5613 in Combination with Daunorubicin and Cytarabine in Newly Diagnosed Patients with Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype with Higher-Risk Features or MLL/KMT2A Rearranged Disease
• Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia
• MYELOMATCH: A Screening Study to Assign People with Myeloid Cancer to a Treatment Study or Standard of Care Treatment within myeloMATCH
• A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who Are Considered High-Risk (Adverse) Acute Myeloid Leukemia as Determined by myeloMATCH; A myeloMATCH Clinical Trial (MM1YA-S01)

• Liver Cancer
• Study for Patients Planning to Undergo Abdominal Surgery for Colorectal, Hepatobiliary, or Gynecologic Cancer
• Testing the combination of the anticancer drug durvalumab with chemotherapy (gemcitabine and cisplatin) at improving outcomes for high-risk liver cancer
• Healthy Adults and Lung/Liver Cancer Patients are invited to be in a research study.

• Lung Cancer
• Research study for adults at risk, diagnosed with, or being evaluated for cancer
• A phase 1b/2, master protocol evaluating the safety, tolerability, pharmacokinetics, and efficacy of sotorasib (AMG 510) in subjects with advanced solid tumors with KRAS p.G12C Mutation (CodeBreaK 101)
• Real-Time Monitoring and Modeling of Symptoms and Adverse Events in Lung Cancer Patients Receiving Oral Targeted Therapies for Tumors with Actionable Mutations
• Phase 2 Trial of Neoadjuvant KRAS G12C directed therapy with Adagrasib (MRTX849) with or without Nivolumab in Resectable Non-Small Cell Lung Cancer (Neo-KAN)
• A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) who Have not Progressed Following Concurrent Chemoradiation Therapy (DeLLphi-306)
• Lung Cancer Surgical Trial
• Healthy Adults and Lung/Liver Cancer Patients are invited to be in a research study.
• Patients with nonsquamous non-small cell lung cancer are needed for a study to evaluate an experimental immunotherapy alone or in combination with chemotherapy
• A Phase Ib Study of AZD9291 (Osimertinib) and CB-839 HCl in Patients with EGFR Mutant Non-Small Cell Lung Cancer – ETCTN 10216
• Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC – EA5181
• Phase 3 randomized study of datopotamab deruxtecan (DS-1062A) versus docetaxel in previously treated advanced non-small cell lung cancer without actionable genomic alterations (TROPION-LUNG01)
• DuRvalumab (MEDI4736) with chEmotherapy as first line treAtment in advanced pleural Mesothelioma - A phase 3 Randomised trial
• A Prospective Randomized Study of ramucirumab plus pembrolizumab versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
• A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
• A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 antibody) in Combination with Cemiplimab (Anti-PD-1 antibody) versus Cemiplimab Monotherapy in First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with Tumors Expressing PD-L1 =50%
• A randomized, double-blind phase 2/3 study of Fianlimab (anti-lag 3 antibody), Cemiplimab (anti-pd-1 antibody), and chemotherapy versus cemiplimab and chemotherapy in first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) irrespective of PD-L1 expression levels.
• A Phase 2 Study of Alisertib in Patients with Extensive Stage Small Cell Lung Cancer
• Phase II study of adagrasib + stereotactic radiosurgery (SRS) for patients with metastatic KRAS G12C-mutated NSCLC with untreated brain metastases (LUN23-618)
• Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
• A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable older adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
• A phase II trial of MOnaliZumab in combination with durvAlumab (MEDI4736) plus platinumbased chemotheRapy for first-line Treatment of extensive stage small cell lung cancer (MOZART)
• A First-in-Human, Open-Label, Dose Escalation and Expansion Study of Orally Administered NX-019 in Patients with Advanced, EGFR Mutant Cancer
• A multicentre, Phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy (CT), followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab, in participants with resectable or borderline resectable stage IIB-IIIB Non-small Cell Lung Cancer (NSCLC)

• Lymphomas
• A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects with Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
• A phase 2 open-label, multicenter study evaluating the safety and efficacy of axicabtagene ciloleucel concomitant with prophylactic steroids in subjects with relapsed or refractory large b-cell lymphoma in the outpatient setting
• A Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination with Oral Decitabine/ Cedazuridine and Oral Decitabine/ Cedazuridine Alone in Subjects with Relapsed/Refractory Peripheral T-cell Lymphoma
• A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-413 in Adult Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
• Adults with Newly Diagnosed Mantle Cell Lymphoma invited to be in a research study comparing three chemotherapy regimens
• A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
• Study for Patients with Peripheral T-Cell Lymphoma (PTCL) or Cutaneous T-Cell Lymphoma (CTCL) Comparing an Investigational Combination of Pembrolizumab (Keytruda) with Decitabine and/or Pralatrexate (PTCL 002)
• A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
• Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
• A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
• Fitness-adapted, pembrolizumab-based therapy for untreated classical Hodgkin lymphoma patients 60 years of age and above (cHL 001)
• A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-333 in Adult Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors
• A Phase 3 Open-label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)
• A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Participants with Relapsed/Refractory Hematologic Malignancies
• A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2)
• A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of an Anti-CD20 X Anti-CD3 BiSpecific Antibody, Versus Investigator’s Choice in Previously Untreated Participants with Follicular Lymphoma (OLYMPIA-1)
• A randomized, open-label study evaluating the efficacy and safety of cemacabtagene ansegedleucel in participants with minimal residual disease after response to first line therapy for large B-cell lymphoma (ALPHA3)
• A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-cell Lymphomas
• Protocol 10601, A phase 1 study of mosunetuzumab with polatuzumab vedotin and lenalidomide (M+Pola+Len) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
• A Phase II trial Evaluating Safety and Efficacy of Epcoritamab with Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma.
• A Phase III, Open-Label, Multicenter, Randomized Study Evaluating Glofitamab as a Single Agent Versus Investigator’s Choice in Patients with Relapsed/Refractory Mantle Cell Lymphoma
• NORM: Nodular lymphocyte-predominant Hodgkin lymphoma patients treated in a randomized phase II trial with either rituximab or mosunetuzumab

• Melanoma
• A Phase 1B/2 Study of OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors and Activating Mutations in the RAS Pathway (Phase 1B) and in Patients with Advanced NRAS-Mutated Melanoma
• Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination with CMP-001 in Patients with Operable Melanoma: Efficacy and Biomarker Study
• A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma
• A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA
• Adults with Metastatic Melanoma to a Single Lymph Node Planning to Undergo Surgery are Invited to Participate in a Research Study.
• A Phase 3, multicenter, randomized, open-label, parallel group, treatment to assess the efficacy and safety of the lifileucel (LN-144, autologous tumor-infiltrating lymphocytes [TIL]) regimen in combination with pembrolizumab monotherapy in participants with untreated, unresectable or metastatic melanoma
• A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab Compared with Pembrolizumab in Patients with Resectable Stage III and IV Melanoma
• A Randomized Phase 2 Study of ATR inhibition in advanced PD-(L) 1-refractory Merkel cell carcinoma
• Study Seeking Adult Patients with Advanced Melanoma Who are Receiving Immune Therapy and Who are Planning to Receive Surgery
• A Phase 2/3, adaptive, randomized, open-label, clinical study to evaluate neoadjuvant and adjuvant V940 (mRNA-4157) in combination with pembrolizumab (MK-3475) versus standard of care, and pembrolizumab monotherapy in participants with resectable locally advanced cutaneous squamous cell carcinoma (LA cSCC) (INTerpath-007)
• A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)

• meningioma
• Seeking Adults with Progressive Meningiomas

• Multiple Myeloma
• Patients With Multiple Myeloma (MM) Are Needed For A Research Study Using an Experimental Cellular Therapy
• Study of Cell Transplantation in Medicare Multiple Myeloma Subjects

• Myelodysplastic Syndrome (MDS)
• Study Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients
• A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients with Newly Diagnosed and Relapsed/Refractory Cancer Indications
• Study for Patients with High Risk Leukemias or Myelodysplastic Syndrome to Start Supportive Care Earlier in the Treatment Regimen

• myelofibrosis
• Study of Oral TP-3654 in Patients with Myelofibrosis
• Database Study of Cell Transplant in Medicare Myelofibrosis Subjects
• Study for Patients with CD 123+ Acute Myeloid Leukemia (AML), Myelofibrosis (MF) or Chronic Myelomonocytic Leukemia (CML)

• Myeloma
• A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
• A Phase 3 Randomized Study Comparing the Study Medication in Combination with Daratumumab SC and Pomalidomide (Tal-DP) or the Study Medication in Combination with Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants with Relapsed or Refractory Multiple Myeloma who have Received at Least 1 Prior Line of Therapy
• A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma
• A Phase 3 Randomized Study Comparing Investigational Medicine Combinations and Investigator’s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide

• Neuropathic Pain
• Research Study for Adults with Chronic Pain

• Oral Cancer
• RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer (KEVLARx)

• Ovarian Cancer
• A phase I/II, first in human, open label, dose escalation study of a cancer-specific plectin (CSP)- targeting functional antibody in solid tumors that are likely to express CSP
• Patients with advanced epithelial ovarian, fallopian tube, or peritoneal carcinoma cancers are needed for a study to research a chemo-immunotherapy.
• Patients with ovarian or peritoneal cancers are needed for a study to research a hormonal drug therapy
• A study to collect information and specimens from patients who will have surgery for a gynecologic condition to use in future research.
• A Phase 1/2 Research Study for Patients with Ovarian Clear Cell Carcinoma or Endometrial Carcinoma or other Advanced Solid Tumors
• A Research Study for Adult Women with Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
• Research study for ovarian cancer patients with BRCA1 mutations to compare two surgical procedures
• Patients with recurrent platinum-resistant ovarian cancer are needed for a study to research the combination of abemaciclib and olaparib
• Women with low-grade serous ovarian cancer are needed for a study to evaluate an investigational drug alone or in combination with a 2nd investigational drug.
• A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN-c3 in Combination with Niraparib in Subjects with Platinum-Resistant Ovarian Cancer
• A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status
• Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer who are Folate Receptor a positive
• Pilot Study to Assess the Efficacy of Aspirin to Improve Immunological Features of Ovarian Tumors
• A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer
• Phase 2 Trial of Niraparib or Niraparib and Bevacizumab Combination in Patients with Recurrent Endometrial and/or Ovarian Cancer with ARID1A Mutation (OU-SCC- ARID1A)
• A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
• A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb®541 in Advanced Solid Tumors

• Pancreatic Cancer
• A phase I/II, first in human, open label, dose escalation study of a cancer-specific plectin (CSP)- targeting functional antibody in solid tumors that are likely to express CSP
• A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-1200 in Participants with Advanced Solid Tumors
• A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Participants with Locally Advanced or Metastatic Solid Tumors
• Adults with Pancreatic Cancer are Invited to Participate in a Research Study

• Pancreatic Cysts
• EA2185 Study: Pancreatic Cyst Screening Comparing Two Methods to Follow Patients with Pancreatic Cysts

• Pediatric Cancer: Relapsed and Refractory Langerhans Cell Histiocytosis
• A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

• Pediatric Cancers: Bone Cancer
• A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

• Pediatric Cancers: Brain Cancer
• Neuroblastoma Biology Studies: A Children's Oncology Group Study

• Pediatric Cancers: Hodgkin's Disease
• A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-Oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma (AHOD2131)

• Pediatric Cancers: Lymphoma
• A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy (ACCL1931)

• Pediatric Cancers: Neuroblastoma
• Neuroblastoma Biology Studies: A Children's Oncology Group Study
• Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

• Pediatric Cancers: Sarcomas
• A Group-Wide Protocol for Collecting and Banking Pediatric Cancer Research Specimens

• Peripheral T-Cell Lymphoma (PTCL)
• Study for Patients with Peripheral T-Cell Lymphoma (PTCL) or Cutaneous T-Cell Lymphoma (CTCL) Comparing an Investigational Combination of Pembrolizumab (Keytruda) with Decitabine and/or Pralatrexate (PTCL 002)
• Study for Patients with Peripheral T-Cell Lymphoma Comparing an Investigational Combination with Standard Treatment

• Peritoneal Cancer
• Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer who are Folate Receptor a positive
• Randomized, multicenter, open-label, phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRa–positive recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second line platinum-based chemotherapy plus bevacizumab

• Primary Central Nervous System Lymphoma (PCNSL)
• Study for Adults with Primary Central Nervous System Lymphoma (PCNSL)

• Prostate
• Research study for adults with Prostate cancer
• Phase 1/2a, Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients with Advanced Prostate Cancer
• Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer
• A Phase 2, Randomized, Open-Label, Study of lorigerlimab with docetaxel or docetaxel alone in Participants with Metastatic Castration-Resistant Prostate Cancer
• A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next generation Hormonal Agent (NHA)
• A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy
• Research Exercise Study Seeking Adult Patients with Metastatic Castrate-Sensitive Prostate Cancer (mCSPC)
• Treating prostate cancer that has come back after surgery with apalutamide and targeted radiation based on PET imaging
• A phase 1/2 study of Anti-PSMAXCD28 with or without Anti-PD-1 in patients with metastatic castration-resistant prostate cancer and other tumors associated with PSMA expression

• Prostate Cancer
• Research study for adults at risk, diagnosed with, or being evaluated for cancer
• Adults with castration-resistant prostate cancer invited to be in a research study
• Research study for adults with recurrent prostate cancer
• Radiation treatment research study for adults with prostate cancer
• Research study for adults with Prostate cancer
• Phase 1/2a, Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients with Advanced Prostate Cancer
• ) A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 in Patients with Metastatic Castration-Resistant Prostate Cancer
• Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer
• A Phase 2, Randomized, Open-Label, Study of lorigerlimab with docetaxel or docetaxel alone in Participants with Metastatic Castration-Resistant Prostate Cancer
• A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next generation Hormonal Agent (NHA)
• A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy
• Research Exercise Study Seeking Adult Patients with Metastatic Castrate-Sensitive Prostate Cancer (mCSPC)
• Treating prostate cancer that has come back after surgery with apalutamide and targeted radiation based on PET imaging
• A phase 1/2 study of Anti-PSMAXCD28 with or without Anti-PD-1 in patients with metastatic castration-resistant prostate cancer and other tumors associated with PSMA expression

• Radiation Therapy
• Research study for adults with recurrent prostate cancer
• Radiation treatment research study for adults with prostate cancer
• Research study for adults with Prostate cancer

• Rectal Cancer
• Research study for adults with Stage II or III Rectal Cancer.

• Sarcoma
• A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)
• Randomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients with Soft Tissue Sarcoma

• Skin Cancer
• Patients with Cutaneous Squamous Cell Carcinoma are needed for a study to research an immunotherapy drug
• Patients with advanced Cutaneous Squamous Cell Carcinoma and being treated with cemiplimab are needed for a research study
• Testing Pembrolizumab versus Observation in Patients with Merkel Cell Carcinoma after Surgery

• Solid Tumors
• The POWER II Trial: Seeking women ages 65 years or older with early-stage, estrogen receptor positive (ER+) breast cancer.
• A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb®541 in Advanced Solid Tumors
• A Phase 1, Open-Label, First in Human, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZX-4081 in Patients with Advanced Solid Tumors
• Adults with advanced and/or metastasized solid tumors who failed usual chemotherapy treatment are invited to be in a research study testing the immunotherapy drug
• A Phase 1/1b Dose Escalation and Cohort Expansion Study of MGC018 in Combination with MGD019 in Participants with Advanced Solid Tumors
• A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage lymphoma proto-oncogene (CBL-B) inhibitor, in Adults with Advanced Malignancies, with Phase 1b Expansion in Select Tumor Types
• : A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 (an antibody drug conjugate targeting tissue factor) as single-agent and combination therapy in subjects with inoperable locally advanced or metastatic solid tumors
• A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Metastatic Solid Tumors Which Have Progressed Despite Standard Treatments
• Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients with Molecularly-Selected Solid Tumors (ComBET)
• Molecular Analysis for Combination Therapy Choice
• A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors

• Stem Cell Transplant
• Patients with allogeneic hematopoietic cell transplants are needed for a study to research an investigative cellular therapy to prevent life threatening viral infections compared to a placebo
• Blood Sample Banking For Future Research
• Study of Cell Transplantation in Medicare Multiple Myeloma Subjects
• Database Study of Cell Transplant in Medicare Myelofibrosis Subjects
• A phase 2, open-label, single-arm, multicohort, multicenter trial to evaluate the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory indolent B-cell non-hodgkin lymphoma (NHL)
• Study for Patients with CD 123+ Acute Myeloid Leukemia (AML), Myelofibrosis (MF) or Chronic Myelomonocytic Leukemia (CML)
• Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies, and Marrow Toxic Injuries

• Transplant
• Safety Study of Cell Transplant with Unlicensed Cord Blood (CB)

• Uterine Cancer
• Research study for adults with gynecological cancer
• A study to collect information and specimens from patients who will have surgery for a gynecologic condition to use in future research.
• Adults with Endometrial cancers invited to be in a research study
• Adults with endometrial cancer invited to be in a research study testing the addition of the immunotherapy drug to the usual chemotherapy treatment
• A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial for Selinexor in Maintenance Therapy after Systemic Therapy for Patients with P53 wild-type, Advanced or Recurrent Endometrial Carcinoma
• A phase 1/2 study of EG-70 as an intravesical administration to patients with BCG-unresponsive NMIBC and high-risk patients who are BCG naïve or received incomplete BCG treatment

• Vaginal/Vulval Cancer
• Research study for adults with gynecological cancer
• A study to collect information and specimens from patients who will have surgery for a gynecologic condition to use in future research.